BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29280214)

  • 1. Thorough in silico and in vitro cDNA analysis of 21 putative BRCA1 and BRCA2 splice variants and a complex tandem duplication in BRCA2 allowing the identification of activated cryptic splice donor sites in BRCA2 exon 11.
    Baert A; Machackova E; Coene I; Cremin C; Turner K; Portigal-Todd C; Asrat MJ; Nuk J; Mindlin A; Young S; MacMillan A; Van Maerken T; Trbusek M; McKinnon W; Wood ME; Foulkes WD; Santamariña M; de la Hoya M; Foretova L; Poppe B; Vral A; Rosseel T; De Leeneer K; Vega A; Claes KBM
    Hum Mutat; 2018 Apr; 39(4):515-526. PubMed ID: 29280214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characterization and cancer risk associated with BRCA1 and BRCA2 splice site variants identified in multiple-case breast cancer families.
    Tesoriero AA; Wong EM; Jenkins MA; Hopper JL; Brown MA; Chenevix-Trench G; Spurdle AB; Southey MC;
    Hum Mutat; 2005 Nov; 26(5):495. PubMed ID: 16211554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional classification of DNA variants by hybrid minigenes: Identification of 30 spliceogenic variants of BRCA2 exons 17 and 18.
    Fraile-Bethencourt E; Díez-Gómez B; Velásquez-Zapata V; Acedo A; Sanz DJ; Velasco EA
    PLoS Genet; 2017 Mar; 13(3):e1006691. PubMed ID: 28339459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiating pathogenic mutations from polymorphic alterations in the splice sites of BRCA1 and BRCA2.
    Claes K; Poppe B; Machackova E; Coene I; Foretova L; De Paepe A; Messiaen L
    Genes Chromosomes Cancer; 2003 Jul; 37(3):314-20. PubMed ID: 12759930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genes.
    Théry JC; Krieger S; Gaildrat P; Révillion F; Buisine MP; Killian A; Duponchel C; Rousselin A; Vaur D; Peyrat JP; Berthet P; Frébourg T; Martins A; Hardouin A; Tosi M
    Eur J Hum Genet; 2011 Oct; 19(10):1052-8. PubMed ID: 21673748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene.
    Bonnet C; Krieger S; Vezain M; Rousselin A; Tournier I; Martins A; Berthet P; Chevrier A; Dugast C; Layet V; Rossi A; Lidereau R; Frébourg T; Hardouin A; Tosi M
    J Med Genet; 2008 Jul; 45(7):438-46. PubMed ID: 18424508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA-based analysis of BRCA1 and BRCA2 gene alterations.
    Bonatti F; Pepe C; Tancredi M; Lombardi G; Aretini P; Sensi E; Falaschi E; Cipollini G; Bevilacqua G; Caligo MA
    Cancer Genet Cytogenet; 2006 Oct; 170(2):93-101. PubMed ID: 17011978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of 30 putative BRCA1 splicing mutations in hereditary breast and ovarian cancer families identifies exonic splice site mutations that escape in silico prediction.
    Wappenschmidt B; Becker AA; Hauke J; Weber U; Engert S; Köhler J; Kast K; Arnold N; Rhiem K; Hahnen E; Meindl A; Schmutzler RK
    PLoS One; 2012; 7(12):e50800. PubMed ID: 23239986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain.
    Campos B; Díez O; Domènech M; Baena M; Balmaña J; Sanz J; Ramírez A; Alonso C; Baiget M
    Hum Mutat; 2003 Oct; 22(4):337. PubMed ID: 12955719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA2 deep intronic mutation causing activation of a cryptic exon: opening toward a new preventive therapeutic strategy.
    Anczuków O; Buisson M; Léoné M; Coutanson C; Lasset C; Calender A; Sinilnikova OM; Mazoyer S
    Clin Cancer Res; 2012 Sep; 18(18):4903-9. PubMed ID: 22753590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The variants BRCA1 IVS6-1G>A and BRCA2 IVS15+1G>A lead to aberrant splicing of the transcripts.
    Gutiérrez-Enríquez S; Coderch V; Masas M; Balmaña J; Diez O
    Breast Cancer Res Treat; 2009 Sep; 117(2):461-5. PubMed ID: 18712473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients.
    Sanz DJ; Acedo A; Infante M; Durán M; Pérez-Cabornero L; Esteban-Cardeñosa E; Lastra E; Pagani F; Miner C; Velasco EA
    Clin Cancer Res; 2010 Mar; 16(6):1957-67. PubMed ID: 20215541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular and in silico analysis of BRCA1 and BRCA2 variants.
    Tommasi S; Pilato B; Pinto R; Monaco A; Bruno M; Campana M; Digennaro M; Schittulli F; Lacalamita R; Paradiso A
    Mutat Res; 2008 Sep; 644(1-2):64-70. PubMed ID: 18694767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterisation of unclassified variants in the BRCA1/2 genes with a putative effect on splicing.
    Brandão RD; van Roozendaal K; Tserpelis D; Gómez García E; Blok MJ
    Breast Cancer Res Treat; 2011 Oct; 129(3):971-82. PubMed ID: 21638052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of three alternative transcripts of the BRCA1 gene in patients with breast cancer and a family history of breast and/or ovarian cancer who tested negative for pathogenic mutations.
    Gambino G; Tancredi M; Falaschi E; Aretini P; Caligo MA
    Int J Mol Med; 2015 Apr; 35(4):950-6. PubMed ID: 25683334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive splicing functional analysis of DNA variants of the BRCA2 gene by hybrid minigenes.
    Acedo A; Sanz DJ; Durán M; Infante M; Pérez-Cabornero L; Miner C; Velasco EA
    Breast Cancer Res; 2012 May; 14(3):R87. PubMed ID: 22632462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA analysis reveals splicing mutations and loss of expression defects in MLH1 and BRCA1.
    Sharp A; Pichert G; Lucassen A; Eccles D
    Hum Mutat; 2004 Sep; 24(3):272. PubMed ID: 15300854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of spliceogenic variants located in regions linked to high levels of alternative splicing: BRCA2 c.7976+5G > T as a case study.
    Montalban G; Fraile-Bethencourt E; López-Perolio I; Pérez-Segura P; Infante M; Durán M; Alonso-Cerezo MC; López-Fernández A; Diez O; de la Hoya M; Velasco EA; Gutiérrez-Enríquez S
    Hum Mutat; 2018 Sep; 39(9):1155-1160. PubMed ID: 29969168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro and in silico analyses of variants in splicing regions of BRCA1 and BRCA2 genes and characterization of novel pathogenic mutations.
    Colombo M; De Vecchi G; Caleca L; Foglia C; Ripamonti CB; Ficarazzi F; Barile M; Varesco L; Peissel B; Manoukian S; Radice P
    PLoS One; 2013; 8(2):e57173. PubMed ID: 23451180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs.
    Vreeswijk MP; Kraan JN; van der Klift HM; Vink GR; Cornelisse CJ; Wijnen JT; Bakker E; van Asperen CJ; Devilee P
    Hum Mutat; 2009 Jan; 30(1):107-14. PubMed ID: 18693280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.